Sotera Health Company Q1 2026 Earnings Call Summary

Sotera Health Company Q1 2026 Earnings Call Summary - Moby

Strategic Performance Drivers and Operational Context

Sterigenics growth was driven by 4.5% pricing and improved volume/mix, despite a 1.7% volume headwind from localized U.S. weather impacts early in the quarter. Nordion's significant 25.8% constant currency revenue growth was primarily attributed to the timing of Cobalt-60 harvest schedules rather than structural market shifts. Nelson Labs performance remained in line with expectations as the segment continues to lap headwinds from the Expert Advisory Services business. Management highlighted a legal milestone in Georgia where all eight bellwether personal injury cases have now been dismissed, with the final five cases dismissed in March after plaintiffs failed to prove general causation. The company is successfully executing a cross-business unit (XBU) strategy, leveraging embedded labs within sterilization facilities to deepen customer integration. Operational efficiency and pricing power drove a 20 basis point expansion in adjusted EBITDA margins, supported by high customer satisfaction scores.

2026 Outlook and Strategic Assumptions

Full-year 2026 guidance assumes constant currency revenue growth of 5% to 6.5%, with pricing expected to land at the midpoint of the 3% to 4% long-term range. Sterigenics Q2 growth is expected to be similar to Q1 due to a difficult year-over-year comparison against the company's strongest growth quarter in 2025. Nelson Labs is projected to return to slight growth in Q2, with margins expected to improve into the low- to mid-30s as routine testing volumes recover. The maintenance schedule for EO facilities will act as a headwind in the first half of 2026 but is expected to become a tailwind in the second half. Capital allocation remains focused on greenfield expansions and EO facility upgrades, with the vast majority of enhancements expected to be complete by year-end 2026.

Leadership Transition and Governance

CEO Michael Petras will transition to Executive Chair in May 2026, with Alton Shader appointed as the new CEO to lead the next phase of global growth. The company's public float increased to approximately 90% following a secondary sale by private equity shareholders in March. Net leverage improved to 3.2x, moving closer to the long-term target range of 2x to 3x following debt repricing and paydowns. Management is monitoring new proposed EPA regulations on EO emissions, stating they are well-positioned to meet requirements regardless of the final rule's stringency.

Q&A Session Highlights

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Story Continues

Sterigenics capacity utilization and future expansion readiness

Management targets approximately 80% utilization and confirmed they are in a 'good spot' globally despite occasional regional pinch points. A new X-ray modality facility is scheduled to come online later this year, with another major expansion planned for the 2027-2028 timeframe.

Impact of large customer onboarding and bioprocessing trends

A meaningful new customer conversion is built into the late-2026 outlook; while significant for morale and validation, it does not require new facility construction. Bioprocessing volumes saw significant year-over-year growth, though management cautioned it remains a relatively small portion of the total business.

Nelson Labs margin recovery and testing volume correlation

Management expects a correlation between rising sterilization volumes and routine testing recovery, though the timing is not always a one-for-one match. Validation project pipelines are beginning to build for the latter half of 2026, supporting the projected margin step-up.

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.

View Comments